Zhiwen Fu

Signal Transduction and Targeted Therapy · 2022

A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom Zhiwen Fu trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. R. Medzhitov
  2. Jagath R Junutula

Papers from Zhiwen Fu's perspective

Ordered by how strongly the researchers Zhiwen Fu trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index (Nature Biotechnology)
  2. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. (Cancer Research)
  3. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates (Nature Biotechnology)
  4. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. (Clinical Cancer Research)
  5. Paul Ehrlich's magic bullet concept: 100 years of progress (Nature Reviews. Cancer)
  6. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. (The Lancet)
  7. The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy in Acute Myeloid Leukaemia : An IndividualPatient Data Meta-analysis of Randomised Trials in Adults (The Lancet Oncology)
  8. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. (Journal of Clinical Oncology)
  9. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer (New England Journal of Medicine)
  10. Competition for FcRn-mediated transport gives rise to short half-life of human IgG3 and offers therapeutic potential

Their papers